With an ever increasing number of patients being treated with IVIg for a wide array of immune-mediated disease, it is important that passive antibody transfer is considered when unexpected ...

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human immunoglobulin G1 (IgG1) monoclonal antibody, brelovitug, to treat chronic ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

Background: The duration of protection after hepatitis B vaccination of infants is unknown. Methods: We determined antibody to hepatitis B surface antigen (anti-HBs) at 4-13 years of age in 363 ...

What our study showed was that during a chronic hepatitis C infection, antibodies on the virus surface form an antibody cluster that persistently stimulates the B cells to mutate," explains lead ...

Learn how the molecule EBC-46 could advance how HIV is treated and how researchers discovered it.

What our study showed was that during a chronic hepatitis C infection, antibodies on the virus surface form an antibody cluster that persistently stimulates the B cells to mutate," explains lead ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu ...

Preterm babies who receive a hepatitis B virus (HBV) vaccine at birth aren't at increased risk of developing a chronic lung ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

About Brelovitug (also known as BJT-778) Brelovitug is a high potency, fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) of the hepatitis B ...